Weijian Guo

机构：Chinese Academy of Sciences, Fudan University Shanghai Cancer Center, National Astronomical Observatories · ORCID：0000-0002-6155-8345

发表论文 30 篇 · 总被引 427 次 · h-index 10

代表论文

• Prediction of Pancreatic Cancer by Serum Biomarkers Using Surface-Enhanced Laser Desorption/Ionization-Based Decision Tree Classification (2005 · Oncology · 被引 93)
• First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis (2022 · International Journal of Cancer · 被引 71)
• Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial (2024 · Nature Medicine · 被引 40)
• Expression and clinical role of NF45 as a novel cell cycle protein in esophageal squamous cell carcinoma (ESCC) (2014 · Tumor Biology · 被引 40)
• Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study (2023 · BMC Medicine · 被引 35)
• Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study (2021 · BioDrugs · 被引 30)